Copeptin: Pathophysiology and potential clinical impact

Ewelina Łukaszyk; Jolanta Małyszko

doi:10.1016/j.advms.2015.07.002

Copeptin: Pathophysiology and potential clinical impact

Adv Med Sci. 2015 Sep;60(2):335-41. doi: 10.1016/j.advms.2015.07.002. Epub 2015 Jul 17.

Authors

Ewelina Łukaszyk¹, Jolanta Małyszko²

Affiliations

¹ 2nd Department of Nephrology and Hypertension with Dialysis Centre, Medical University of Bialystok, Bialystok, Poland.
² 2nd Department of Nephrology and Hypertension with Dialysis Centre, Medical University of Bialystok, Bialystok, Poland. Electronic address: [email protected].

PMID: 26233637
DOI: 10.1016/j.advms.2015.07.002

Abstract

Copeptin, a C-terminal part of the precursor pre-provasopressin is a novel biomarker of arginine-vasopressin (AVP) system. Measurements of AVP concentration are not used in clinical practice because of technical difficulties. Copeptin is synthesized in stoichiometric ratio with AVP, hence it reflects vasopressin concentration in human plasma and serum. This review outlines current research concerning the role of copeptin as a prognostic marker in different diseases and its potential clinical value.

Keywords: Chronic heart failure; Chronic kidney disease; Copeptin; Vasopressin.

Publication types

Review

MeSH terms

Animals
Arginine Vasopressin / metabolism*
Biomarkers / metabolism
Glycopeptides / metabolism*
Heart Failure / metabolism
Humans
Renal Insufficiency, Chronic / metabolism

Substances

Biomarkers
Glycopeptides
copeptins
Arginine Vasopressin